Pfizer-BioNTech’s COVID-19 Booster Gets FDA Approval for People 18 & Above

Pfizer-BioNTech’s COVID-19 Booster Gets FDA Approval for People 18 & Above

The booster dose of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine has received extended authorization for emergency use from the U.S. Food and Drug Administration (FDA) for people aged 18 years and older. 

The booster dose provided by the healthcare companies is to be administered a minimum of six months after the primary vaccination and at the same dosage level. 

The U.S. regulator’s decision was based on the clinical data, which demonstrated strong immune responses following the booster dose of the vaccine, exceeding the response reflected after two-dose primary vaccinations. Additionally, these data show that the vaccine has a high potential to protect against tested variants, including Delta.